Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by XTX Topco Ltd

Key Points

• XTX Topco Ltd has reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 57.3%, selling 20,302 shares and now owning 15,144 shares worth approximately $595,000.
• Twist Bioscience's stock has dropped by 8.9%, with current trading around $27.52, while analysts have mixed ratings and varying price targets for the stock.
• The company reported earnings of ($0.47) per share for the last quarter, surpassing analysts' estimates, with a total revenue of $96.06 million.

XTX Topco Ltd lowered its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 57.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,144 shares of the company's stock after selling 20,302 shares during the quarter. XTX Topco Ltd's holdings in Twist Bioscience were worth $595,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TWST. Versant Capital Management Inc lifted its position in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after purchasing an additional 580 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Twist Bioscience in the fourth quarter worth $43,000. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the fourth quarter worth $58,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Twist Bioscience in the first quarter worth $201,000.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research report on Monday. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday. Robert W. Baird dropped their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Guggenheim reaffirmed a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.40.

Insider Activity

In related news, CEO Emily M. Leproust sold 2,802 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $83,359.50. Following the completion of the sale, the chief executive officer directly owned 649,630 shares in the company, valued at $19,326,492.50. This trade represents a 0.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,109 shares of company stock worth $425,962. Company insiders own 3.01% of the company's stock.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded up $0.64 during trading hours on Friday, reaching $25.64. 1,968,975 shares of the stock traded hands, compared to its average volume of 1,386,274. Twist Bioscience Corporation has a one year low of $24.28 and a one year high of $55.33. The company has a quick ratio of 4.24, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -17.68 and a beta of 2.36. The company has a 50 day moving average price of $34.47 and a 200 day moving average price of $38.09.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.